Problems › Should We Enter a New Market? › Professional Services
Market attractiveness is the easy half. Right to win is the half that decides the outcome. This page works through it for professional services firms specifically — including an unedited excerpt from a real analysis of a professional services firm.
Market attractiveness is the easy half. Right to win is the half that decides the outcome. What makes this harder for professional services firms is structural: partner compensation rationally pays people not to sell the highest-margin product in the firm. Any credible answer therefore has to hold billable utilisation and realisation in the same view, which is exactly where most internal analysis stops because the two live in different systems.
New markets get evaluated on size and growth, both of which are knowable and neither of which predicts success. The predictive question is what you already have that transfers — a customer relationship, a distribution route, a cost position, a body of data — and what has to be built from nothing.
A market can be highly attractive and a bad idea for you specifically. The reverse is also true: a dull market where you have a structural advantage will usually outperform an exciting one where you start level with everyone.
The other discipline is a stated kill criterion before entry, because market entries are unusually good at consuming budget quietly for years on the argument that they are nearly there.
These three together are the signature. One on its own usually points somewhere else.
✓ The case rests mainly on market size and growth rate
✓ Nobody has written down what would make you stop
✓ The existing business is flat and the new market is being asked to fix it
The move that usually makes it worse. Entering because the core business has stalled, which takes management attention away from the problem that actually needs it.
It is for you if you run or finance a professional services firm and the case rests mainly on market size and growth rate. It is the situation where the numbers are available but nobody has put them in an order that produces a decision.
It is not for you if Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Below is an excerpt from a real run of this analysis on a professional services firm. It is a sample profile rather than a customer, and it is unedited engine output — this is the format you get, on your own numbers.
The subject is Aldergate Partners, a sample company profile used for testing rather than a customer — $88M revenue, 310 people.
Excerpt from a real Percision run · Cost Reduction & Efficiency · sample company profile
The move. Re-align partner economics so the diagnostic that already converts 63% of the time becomes the default first sale.
| Investment required | $0.9–1.1M total over 12 months: $0.4M for partner-success function (3 FTE), $0.3M for vertical-IP playbook development (4 FTE from existing bench), $0.2M for compensation-model simulation. |
| Expected return | Incremental EBITDA of $2.4–3.2M annually once 40 diagnostics/year achieved; payback period 4–6 months after compensation redesign goes live. |
| Revenue, year 1 | $60.5–62.0M (base case assumes 28 diagnostics sold, 65% attach rate) |
| Revenue, year 2 | $66–69M (40 diagnostics, 70% attach rate, vertical-IP packages live) |
| Revenue, year 3 | $74–78M (52 diagnostics, 75% attach rate, UK/EU regulatory playbooks optional) |
| Exit criteria | Strategy should be reversed if, within 12 months, (a) diagnostic attach rate falls below 45% for two consecutive quarters, OR (b) ≥4 partners depart (18% attrition), OR (c) partner cash-impact delta is negative for ≥50% of partners for two consecutive quarters. |
This is one move out of a full analysis. Read a complete report — every page, no email required.
This question routes to Market Entry & Expansion Strategy, one of 29 engagements the platform runs. For professional services firms it works through billable utilisation, realisation, revenue per partner and engagement gross margin, then produces the sequence rather than a list of options — which move first, what it funds, and the observation that would say the sequence is wrong.
You watch the analysis get built before paying anything. Read a complete report here if you would rather see the depth first.
List what you already own that the new market values, and what a credible incumbent there owns that you do not. If the second list is longer and includes anything structural — distribution, regulation, data depth — entry is a build, not an extension.
Set the number before you start, and treat exceeding it as the kill criterion rather than as a reason to invest more. Most failed entries were never killed, only slowly starved.
Whichever reuses more of what you already have. Geography usually reuses the product and rebuilds distribution; a new segment usually reuses distribution and rebuilds the product. Whichever rebuild is smaller is the safer bet.
Materially, yes. Partner compensation rationally pays people not to sell the highest-margin product in the firm — which changes both the diagnosis and the order of the fixes. The metrics that decide it here are billable utilisation, realisation, revenue per partner, and an answer built on industry-general benchmarks will usually point at the wrong one first.
Less than most people expect. Your last twelve months of revenue and cost split the way you already split it, plus whatever you hold on billable utilisation and realisation. The analysis is explicit about what it is assuming where your data stops, which is more useful than waiting for numbers you may never have.
Percision is the wrong tool if you already know the answer and only need execution capacity, or if the business is pre-revenue — then the constraint is evidence about the market, not analysis of your own figures. Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library. Also wrong if you need facilitation, politics, or someone to sit with a lender or buyer. Those are human jobs.
Percision is not a lawyer, tax advisor, auditor, licensed appraiser, clinical or regulatory filer, or an AI implementation shop. It does not do HR casework, creative-only brand work, or impersonate a named consulting firm. It is a strategy analysis engine — not a template library.
Describe the situation in your own words and we will tell you which analysis answers it — before you sign up for anything.
Describe my situation →Prefer to skip ahead? Go straight to the free diagnostic.